13G Filing: Viking Global and Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics Inc. (NASDAQ:ABEO): Andreas Halvorsen’s Viking Global filed an amended 13D.

You can check out Viking Global’s latest holdings and filings here.

Please follow Viking Global (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Viking Global or update its stock holdings.

Follow Andreas Halvorsen's Viking Global

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 2,238,720 0 2,238,720 2,238,720 5.6%
Viking Global Performance 0 1,590,000 0 1,590,000 1,590,000 3.9%
Viking Global Equities 0 542,190 0 542,190 542,190 1.3%
Viking Global Equities II 0 31,800 0 31,800 31,800 0.1%
VGE III Portfolio Ltd 0 1,016,010 0 1,016,010 1,016,010 2.5%
Viking Long Fund GP 0 648,720 0 648,720 648,720 1.6%
Viking Long Fund Master Ltd 0 648,720 0 648,720 648,720 1.6%
O. Andreas Halvorsen 0 2,238,720 0 2,238,720 2,238,720 5.6%
David C. Ott 0 2,238,720 0 2,238,720 2,238,720 5.6%
Rose S. Shabet 0 2,238,720 0 2,238,720 2,238,720 5.6%

Follow Andreas Halvorsen's Viking Global

Page 1 of 18 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________

Schedule 13G
________________

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934*

Abeona Therapeutics Inc.
(Name of Issuer)

Common stock
(Title of Class of Securities)

00289Y107
(CUSIP Number)

September 22, 2017
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

___________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 2 of 18 – SEC Filing

Schedule 13G PAGE 2 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Investors LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,238,720
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,238,720
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,238,720
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.6%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 3 of 18 – SEC Filing

Schedule 13G PAGE 3 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Performance LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
1,590,000
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
1,590,000
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,590,000
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
3.9%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 4 of 18 – SEC Filing

Schedule 13G PAGE 4 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Equities LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
542,190
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
542,190
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
542,190
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.3%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 5 of 18 – SEC Filing

Schedule 13G PAGE 5 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Equities II LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
31,800
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
31,800
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
31,800
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.1%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 6 of 18 – SEC Filing

Schedule 13G PAGE 6 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
VGE III Portfolio Ltd.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
1,016,010
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
1,016,010
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,016,010
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
2.5%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
CO
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 7 of 18 – SEC Filing

Schedule 13G PAGE 7 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Long Fund GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
648,720
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
648,720
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
648,720
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.6%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 8 of 18 – SEC Filing

Schedule 13G PAGE 8 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Long Fund Master Ltd.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
648,720
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
648,720
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
648,720
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.6%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
CO
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 9 of 18 – SEC Filing

Schedule 13G PAGE 9 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
O. Andreas Halvorsen
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Norway
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,238,720
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,238,720
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,238,720
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.6%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 10 of 18 – SEC Filing

Schedule 13G PAGE 10 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
David C. Ott
_____________________________________________________________________________

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________

(3) SEC USE ONLY
_____________________________________________________________________________

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,238,720
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,238,720
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,238,720
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.6%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 11 of 18 – SEC Filing

Schedule 13G PAGE 11 of 18

CUSIP No. 00289Y107
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Rose S. Shabet
_____________________________________________________________________________

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________

(3) SEC USE ONLY
_____________________________________________________________________________

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,238,720
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,238,720
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,238,720
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.6%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 12 of 18 – SEC Filing

Schedule 13G PAGE 12 of 18

CUSIP No. 00289Y107

ITEM 1(a). NAME OF ISSUER:
Abeona Therapeutics Inc.

ITEM 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
3333 Lee Parkway, Suite 600
Dallas, Texas 75219

ITEM 2(a). NAME OF PERSON FILING:
Viking Global Investors LP (“VGI”),
Viking Global Performance LLC (“VGP”),
Viking Global Equities LP (“VGE”),
Viking Global Equities II LP (“VGEII”),
VGE III Portfolio Ltd. (“VGEIII”),
Viking Long Fund GP LLC (“VLFGP”),
Viking Long Fund Master Ltd. (“VLFM”),
O. Andreas Halvorsen, David C. Ott and
Rose S. Shabet (collectively, the “Reporting Persons”)

ITEM 2(b). ADDRESS OF PRINCIPAL OFFICE OR, IF NONE, RESIDENCE:
The business address of each of the Reporting Persons is
55 Railroad Avenue, Greenwich, Connecticut 06830.

ITEM 2(c). CITIZENSHIP:
VGI, VGE and VGEII are Delaware limited partnerships;
VGEIII and VLFM are Cayman Islands exempted companies; and
VGP and VLFGP are Delaware limited liability companies.
O. Andreas Halvorsen is a citizen of Norway.
David C. Ott and Rose S. Shabet are citizens of
the United States.

ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common stock (“Common Stock”)

ITEM 2(e). CUSIP NUMBER: 00289Y107

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c),
CHECK WHETHER THE PERSON FILING IS A:

(a) [ ] Broker or dealer registered under Section 15 of the
Act

(b) [ ] Bank as defined in Section 3(a)(6) of the Act

(c) [ ] Insurance Company as defined in Section 3(a)(19) of
the Act

(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940

(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940: see Rule 13d-
1(b)(1)(ii)(E)

(f) [ ] Employee Benefit Plan, Pension Fund which is subject
to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see Rule 13d-
1(b)(1)(ii)(F)

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 13 of 18 – SEC Filing

Schedule 13G PAGE 13 of 18

CUSIP No. 00289Y107

(g) [ ] Parent Holding Company, in accordance with Rule 13d-
1(b)(ii)(G)

(h) [ ] Savings Associations as defined in Section 3(b) of the
Federal Deposit Insurance Act

(i) [ ] Church Plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940

(j) [ ] A non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J)

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J), please specify
the type of institution:

ITEM 4. OWNERSHIP.

A. VGI
(a) Amount beneficially owned: 2,238,720
(b) Percent of class: 5.6%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,238,720
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,238,720

VGI provides managerial services to VGE, VGEII, VGEIII and VLFM.
VGI has the authority to dispose of and vote the shares
of Common Stock.

Based on Rule 13d-3 of the Securities Exchange Act of 1934,
as amended (the “Act”), VGI may be deemed to beneficially
own the shares of Common Stock directly held by VGE, VGEII,
VGEIII and VLFM. VGI does not directly own
any shares of Common Stock.

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 14 of 18 – SEC Filing

Schedule 13G PAGE 14 of 18

CUSIP No. 00289Y107

B. VGP
(a) Amount beneficially owned: 1,590,000
(b) Percent of class: 3.9%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,590,000
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,590,000

VGP, as the general partner of VGE and VGEII, has the
authority to dispose of and vote the shares of Common Stock
directly owned by VGE and VGEII. VGP serves as investment
manager to VGEIII and has the authority to dispose of and vote
the shares of Common Stock directly owned by VGEIII. VGP does
not directly own any shares of Common Stock.

Based on Rule 13d-3 of the Act, VGP may be deemed to
beneficially own the shares of Common Stock directly held by
VGE, VGEII and VGEIII.

C. VLFGP
(a) Amount beneficially owned: 648,720
(b) Percent of class: 1.6%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
648,720
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 648,720

VLFGP serves as the investment manager of VLFM and has the
authority to dispose of and vote the shares of Common Stock
directly owned by VLFM. VLFGP does not directly own
any shares of Common Stock.

Based on Rule 13d-3 of the Act, VLFGP may be deemed to
beneficially own the shares of Common Stock directly held by
VLFM.

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 15 of 18 – SEC Filing

Schedule 13G PAGE 15 of 18

CUSIP No. 00289Y107

D. VGE
(a) Amount beneficially owned: 542,190
(b) Percent of class: 1.3%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
542,190
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 542,190

VGE has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its general partner, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGE.

E. VGEII
(a) Amount beneficially owned: 31,800
(b) Percent of class: 0.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
31,800
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 31,800

VGEII has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its general partner, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGEII.

F. VGEIII
(a) Amount beneficially owned: 1,016,010
(b) Percent of class: 2.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,016,010
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,016,010

VGEIII has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its investment manager, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGEIII.
Viking Global Equities III Ltd. (a Cayman Islands exempted
company) invests substantially all of its assets through VGEIII.

G. VLFM
(a) Amount beneficially owned: 648,720
(b) Percent of class: 1.6%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
648,720
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 648,720

VLFM has the authority to dispose of and vote the
shares of Common Stock directly owned by it, which power may
be exercised by its investment manager, VLFGP, and by VGI,
an affiliate of VLFGP, which provides managerial services
to VLFM. Viking Long Fund LP (a Delaware limited partnership)
and Viking Long Fund III Ltd. (a Cayman Islands exempted
company), through its investment in Viking Long Fund Intermediate
LP (a Cayman Islands limited partnership), invest substantially
all of their assets through VLFM.

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 16 of 18 – SEC Filing

Schedule 13G PAGE 16 of 18

CUSIP No. 00289Y107

H. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet
(a) Amount beneficially owned: 2,238,720
(b) Percent of class: 5.6%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,238,720
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,238,720

Mr. Halvorsen, Mr. Ott and Ms. Shabet, as
Executive Committee Members of Viking Global Partners LLC,
general partner of VGI (“VGPL”), VGP and VLFGP,
have shared authority to dispose of and vote the shares of
Common Stock beneficially owned by VGI, VGP and VLFGP.
None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly
owns any shares of Common Stock.

Based on Rule 13d-3 of the Act, each may be deemed to beneficially
own the shares of Common Stock directly held by VGE, VGE II,
VGEIII and VLFM.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the
date hereof the Reporting Persons has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following.[]

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Yes, see Item 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))
By signing below each Reporting Person certifies that, to the best
of its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and not held in connection with or as a
participant in any transaction having that purpose or effect.

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 17 of 18 – SEC Filing

Schedule 13G PAGE 17 of 18

CUSIP No. 00289Y107

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief,
the undersigned certify that the information set forth in this statement is
true, complete and correct.

DATED: October 2, 2017

/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD.

/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD.

/s/ ROSE S. SHABET
By: Rose S. Shabet – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD.

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)

Page 18 of 18 – SEC Filing

Schedule 13G PAGE 18 of 18

CUSIP No. 00289Y107

EXHIBIT A – JOINT FILING AGREEMENT

This joint filing agreement is made and entered into as of
this 2nd day of October, 2017, by and among Viking Global Investors LP,
Viking Global Performance LLC, Viking Global Equities LP, Viking Global
Equities II LP, VGE III Portfolio Ltd., Viking Long Fund GP LLC, Viking Long
Fund Master Ltd., O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

The parties hereby agree to jointly prepare and file a Schedule 13G
with respect to Abeona Therapeutics Inc., as well as any amendments thereto,
pursuant to the Securities Exchange Act of 1934, as amended.

IN WITNESS WHEREOF, the parties hereto have executed this agreement
as of the date first set forth above.

Dated: October 2, 2017

/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD.

/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD.

/s/ ROSE S. SHABET
By: Rose S. Shabet – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD.

Follow Abeona Therapeutics Inc. (NASDAQ:ABEO)